Bicara Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company, raised $108M in Series B funding.
The round was led by Red Tree Venture Capital and RA Capital Management with participation from F-Prime Capital, Eight Roads Ventures, Invus, Piper Heartland Healthcare Capital and Premji Invest. New investors include Omega Funds, Bioqube Ventures, Acorn Bioventures and Janus Henderson Investors. In conjunction with the financing, Krishna Polu, M.D., Principal at Red Tree Venture Capital, Jake Simson, Ph.D., Partner at RA Capital Management, and Ketan Patel, M.D., Partner at F-Prime Capital, will join Bicara’s Board of Directors.
The company intends to use the funds to support future studies of lead program BCA101, currently in Phase 1/1b clinical development in head and neck cancer, and pipeline growth.
Led by CEO Claire Mazumdar, Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the targeted therapy and tumor modulators. Its bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. Its lead asset, BCA101, a first-in-class EGFR / TGF-β-trap bifunctional antibody, is currently enrolling patients in a Phase 1/1b study.